Adma

Perspective Therapeutics Introduces “Pre-Targeting” Theranostic Technology Platform

Retrieved on: 
Thursday, February 1, 2024
Stony Brook University, Toxicity, National Cancer Institute, Research, Riitta Jallinoja, NIH, CB7, CATX, Patient, Safety, Diagnosis, Adma, CEA, Ligand, Therapy, Radiation, Journal, Assistant professor, Cancer, Neoplasm, Radiology, Bangladesh Technical Education Board, Radioactive decay, Nuclear medicine, Vaccine

This antibody is chemically modified to include the CB7 chemical entity and accumulates over time at the tumor site.

Key Points: 
  • This antibody is chemically modified to include the CB7 chemical entity and accumulates over time at the tumor site.
  • Then, a radionuclide held tightly by Perspective’s proprietary chelator attached to an Adma group is administered.
  • The research conducted at Stony Brook University refines the understanding of the potential of the proprietary CB7-Adma pre-targeting platform for image-guided radionuclide therapy for oncology.
  • The technology was first described by Stony Brook University researchers, Jacob L. Houghton, Ph.D. and Vilma I.J.

ADMA Biologics to Report Second Quarter 2021 Financial Results on August 11, 2021

Retrieved on: 
Wednesday, August 4, 2021
Life sciences, Anatomy, Biotechnology, Blood, Transfusion medicine, Biopharmaceutical, Pharmaceutical industry, Adma, Boca Raton, Florida, Blood plasma

RAMSEY, N.J. and BOCA RATON, Fla., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (ADMA or the Company), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it will report financial results for the second quarter ended June 30, 2021 on Wednesday, August 11, 2021 after the U.S. financial markets close.

Key Points: 
  • RAMSEY, N.J. and BOCA RATON, Fla., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (ADMA or the Company), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it will report financial results for the second quarter ended June 30, 2021 on Wednesday, August 11, 2021 after the U.S. financial markets close.
  • ADMAs management team will host a live conference call and audio webcast on that date at 4:30 p.m.
  • ET to discuss its financial results and other Company updates.
  • ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida.

ADMA Biologics Announces Successful Completion of FDA Pre-Approval Manufacturing Facility Inspection

Retrieved on: 
Tuesday, July 20, 2021
Life sciences, Biotechnology, Health sciences, Transfusion medicine, Biopharmaceutical, Pharmaceutical industry, Pharmacy, Blood plasma, Adma, Food and Drug Administration

With this favorable inspection outcome, we are anticipating receiving approval for the VanRx in the second half of 2021.

Key Points: 
  • With this favorable inspection outcome, we are anticipating receiving approval for the VanRx in the second half of 2021.
  • Additionally, the expected approval will enable ADMA to onboard third-party fill-finish contracts as a new and accretive revenue source.
  • ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases.
  • ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida.

ADMA Biologics to Participate in the Raymond James Human Health Innovation Virtual Conference

Retrieved on: 
Monday, June 14, 2021
Life sciences, Biotechnology, Health sciences, Pharmaceutical industry, Biopharmaceutical, Pharmacy, Adma, Food and Drug Administration, Boca Raton, Florida, Blood plasma

RAMSEY, N.J. and BOCA RATON, Fla., June 14, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (the Company), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that Adam Grossman, President and Chief Executive Officer, will participate in a fireside chat at the Raymond James Human Health Innovation Virtual Conference on June 21, 2021 at 9:20 a.m.

Key Points: 
  • RAMSEY, N.J. and BOCA RATON, Fla., June 14, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (the Company), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that Adam Grossman, President and Chief Executive Officer, will participate in a fireside chat at the Raymond James Human Health Innovation Virtual Conference on June 21, 2021 at 9:20 a.m.
  • A webcast of the event will be available on the Companys website at https://ir.admabiologics.com/events-webcasts and will be archived for 90 days following the event.
  • ADMA Biologics is an end-to-end American commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases.
  • ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida.

ADMA Biologics to Participate in the Jefferies Virtual Healthcare Conference

Retrieved on: 
Wednesday, May 26, 2021
Life sciences, Biotechnology, Health sciences, Pharmaceutical industry, Biopharmaceutical, Pharmacy, Adma, Food and Drug Administration, Boca Raton, Florida, Blood plasma

RAMSEY, N.J. and BOCA RATON, Fla., May 26, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (the Company), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that Adam Grossman, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 2, 2021 at 4:00 p.m.

Key Points: 
  • RAMSEY, N.J. and BOCA RATON, Fla., May 26, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (the Company), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that Adam Grossman, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 2, 2021 at 4:00 p.m.
  • A webcast of the event will be available on the Companys website at https://ir.admabiologics.com/events-webcasts and will be archived for 90 days following the event.
  • ADMA Biologics is an end-to-end American commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases.
  • ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida.

ADMA Biologics to Report First Quarter 2021 Financial Results on May 12, 2021

Retrieved on: 
Wednesday, May 5, 2021
Life sciences, Biotechnology, Adma, Boca Raton, Florida, Biopharmaceutical

b'RAMSEY, N.J. and BOCA RATON, Fla., May 05, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (\xe2\x80\x9cADMA\xe2\x80\x9d), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it will report financial results for the first quarter ended March 31, 2021 on Wednesday, May 12, 2021 after the U.S. financial markets close.

Key Points: 
  • b'RAMSEY, N.J. and BOCA RATON, Fla., May 05, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (\xe2\x80\x9cADMA\xe2\x80\x9d), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it will report financial results for the first quarter ended March 31, 2021 on Wednesday, May 12, 2021 after the U.S. financial markets close.
  • ADMA\xe2\x80\x99s management team will host a live conference call and audio webcast on that date at 4:30 p.m.
  • A live audio webcast of the call will be available under \xe2\x80\x9cEvents & Webcasts\xe2\x80\x9d in the investor section of the Company\xe2\x80\x99s website, https://ir.admabiologics.com/events-webcasts .
  • ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida.

ADMA Biologics Receives FDA Approval for Increased IVIG Production Scale

Retrieved on: 
Wednesday, April 28, 2021
Branches of biology, Anatomy, Clinical medicine, Transfusion medicine, Blood products, Blood, Blood plasma, Hematology, Plasmapheresis, Adma

ADMA now has FDA approval to produce BIVIGAM\xc2\xae at an expanded capacity with the same high quality as the previous manufacturing scale, while using the same equipment, release testing assays, disposables and labor force.

Key Points: 
  • ADMA now has FDA approval to produce BIVIGAM\xc2\xae at an expanded capacity with the same high quality as the previous manufacturing scale, while using the same equipment, release testing assays, disposables and labor force.
  • The Company anticipates this will translate into meaningful gross margin improvement as production throughput flows through the standard 7 to 12-month manufacturing cycle for plasma-derived therapies.
  • ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida.
  • Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products.

ADMA Biologics Opens Newest ADMA BioCenters Plasma Collection Facility in Goose Creek, S.C.

Retrieved on: 
Monday, April 26, 2021
Anatomy, Blood, Branches of biology, Body fluids, Transfusion medicine, Medical technology, Fractionation, Blood plasma, Adma

The Governor\xe2\x80\x99s ribbon cutting at our newest plasma collection facility marks the latest achievement in what has been an excellent start to 2021 for ADMA across all of its business units,\xe2\x80\x9d said Adam Grossman, President and Chief Executive Officer of ADMA.

Key Points: 
  • The Governor\xe2\x80\x99s ribbon cutting at our newest plasma collection facility marks the latest achievement in what has been an excellent start to 2021 for ADMA across all of its business units,\xe2\x80\x9d said Adam Grossman, President and Chief Executive Officer of ADMA.
  • Accordingly, ADMA expects to file its BLA for the Goose Creek, S.C. plasma collection facility in approximately 3 months from center opening and anticipates a standard 12-month BLA review period by the FDA.
  • Managed by a team of experts who have decades of experience in the specialized field of plasma collection, ADMA BioCenters provides a safe, professional and pleasant donation environment.
  • ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida.

ADMA Biologics Reports Fourth Quarter and Full Year 2020 Financial Results

Retrieved on: 
Thursday, March 25, 2021
Life sciences, Biotechnology, Adma, Boca Raton, Florida, Biopharmaceutical

ET

Key Points: 
  • ET
    RAMSEY, N.J. and BOCA RATON, Fla., March 25, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (ADMA or the Company), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today reported financial results for its fiscal fourth quarter and year ended December 31, 2020 and provided an overview of recent progress and accomplishments.
  • Achieved fourth quarter 2020 total revenues of $14.0 million, compared to $12.0 million for the fourth quarter of 2019, representing an approximately 16% increase.
  • The revenue growth for the fourth quarter of 2020, compared to the fourth quarter of 2019, was favorably impacted by the continued commercial ramp up of our IVIG product portfolio.
  • ADMA will host a conference call today, March 25, 2021, at 4:30 p.m. Eastern Time, to discuss the fiscal fourth quarter and full year 2020 financial results and recent corporate updates.

ADMA Biologics to Report Fourth Quarter and Full Year 2020 Financial Results on March 25, 2021

Retrieved on: 
Thursday, March 18, 2021
Life sciences, Anatomy, Biotechnology, Blood, Pharmaceutical industry, Biopharmaceutical, Pharmacy, Adma, Boca Raton, Florida, Blood plasma

RAMSEY, N.J. and BOCA RATON, Fla., March 18, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it will report financial results for the fourth quarter and full year ending December 31, 2020 on Thursday, March 25, 2021 after the U.S. financial markets close.

Key Points: 
  • RAMSEY, N.J. and BOCA RATON, Fla., March 18, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it will report financial results for the fourth quarter and full year ending December 31, 2020 on Thursday, March 25, 2021 after the U.S. financial markets close.
  • ADMAs management team will host a live conference call and audio webcast on that date at 4:30 p.m.
  • ET to discuss its financial results and other company updates.
  • ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida.